Quick answer: peptide cycling means taking a peptide for a set time, then stopping for a break (“on/off” protocols) to prevent tolerance or side effects. Human evidence is thin. Some growth hormone-releasing peptides show partial, reversible tolerance: one 16-week study saw the hexarelin response drop by about half, then recover after 4 weeks off.[1] But approved peptides are labeled for continuous use, and stopping a GLP-1 drug usually brings weight back.[4][5]
This guide explains where cycling ideas come from and what is known. It is educational: never stop, pause or restart a prescribed peptide without your prescriber, and do not self-administer unapproved products. More background is on our peptide basics hub.
Where peptide cycling comes from
Cycling schedules such as “8 weeks on, 4 off” or “5 days on, 2 off” are borrowed largely from bodybuilding and anabolic steroid culture. They spread through forums and seller websites. None of the approved peptide labels we reviewed use an on/off schedule; tesamorelin is given daily, and tirzepatide weekly, for as long as treatment continues.[6][7]
The main claims behind cycling are:
- Tolerance (desensitization): receptors respond less after repeated stimulation.
- Safety: breaks let hormone levels or blood sugar return to baseline.
- “Resetting” the body’s own hormone production.
Why tolerance can happen
Many peptides act on receptors on the surface of cells. When a receptor is stimulated over and over, cells can respond less: receptors may be pulled inside the cell, uncoupled from their signaling machinery, or made in smaller numbers. Pharmacologists call this desensitization or tachyphylaxis. It is a real phenomenon, but it varies hugely by receptor, dose, timing and person.
Three points follow from that:
- Tolerance is not automatic. Some peptides show it in humans, others do not, and a drop in one lab marker may not mean the treatment stops working.[1][2]
- The size and speed matter. A partial drop that levels off is very different from a steady decline to zero.
- Recovery can be measured. For hexarelin, the response returned to baseline within 4 weeks off, which is the only human data we found that directly tests a “break”.[1]
Cycling schedules sold online rarely cite any of this; most give fixed week counts with no source.
Claims vs evidence
| Claim | What human data show | Strength |
|---|---|---|
| GH peptides lose effect with daily use | Hexarelin: GH response fell from 19.1 to 10.5 (area under curve) over 16 weeks, recovered after 4 weeks off; IGF-1 unchanged[1] | Small studies (12 adults; 7 children) |
| Tolerance cancels the benefit | In children, the hexarelin response halved but growth speed still rose from 5.3 to 7.4 cm/year[2] | One small study |
| All GH secretagogues need breaks | MK-677 kept GH and IGF-1 at young-adult levels over 2 years of daily use[3] | One 65-person trial |
| Breaks are harmless for GLP-1s | Stopping led to large weight regain[4][5] | Large randomized trials |
| Healing peptides need cycling | No controlled human data exist for BPC-157 or TB-500 | None |
Growth hormone peptides: some tolerance, not the whole story
Hexarelin. In 12 healthy older adults given twice-daily injections for 16 weeks, the growth hormone response to a test dose dropped significantly by weeks 4 and 16. Four weeks after stopping, it returned to baseline. IGF-1, the main downstream hormone, did not change significantly over the study.[1] A pediatric study found a similar early drop that then stayed stable for 6 months, without blocking a gain in growth speed.[2] See our hexarelin profile.
MK-677. By contrast, a 2-year randomized trial found daily MK-677 raised growth hormone and IGF-1 to the levels of healthy young adults, with 2-year analyses confirming the 1-year results.[3] That argues against the idea that every GH secretagogue stops working without breaks. It also showed rising fasting glucose and lower insulin sensitivity, a reason for monitoring rather than cycling.[3]
Tesamorelin. Its label manages risk with monitoring, not cycling: check IGF-1 and glucose during treatment and consider stopping if IGF-1 stays very high.[6]
Results for one peptide do not transfer to another. There are no published human trials comparing cycled vs continuous use for ipamorelin, CJC-1295 or sermorelin.
GLP-1 drugs: breaks usually mean regain
- STEP 1 extension: people lost 17.3% of body weight over 68 weeks on semaglutide. A year after stopping, they had regained 11.6 percentage points, leaving a net loss of 5.6%.[4]
- SURMOUNT-4: after 36 weeks on tirzepatide (20.9% loss), people switched to placebo regained 14.0% of their weight over the next year, while those who continued lost a further 5.5%. 89.5% of those who continued kept at least 80% of their loss, vs 16.6% on placebo.[5]
The Zepbound label gives specific rules for missed doses, which is one reason any gap should be planned with the prescriber.[7] For more, see stopping GLP-1 and missed GLP-1 dose.
Healing and “research” peptides
Cycling advice for BPC-157, TB-500 and similar compounds has no human trial behind it, because the compounds themselves have not been through controlled human trials. FDA has listed BPC-157 among substances that may pose significant safety risks in compounding.[8] A break schedule cannot make an untested product safer.
How to talk to your prescriber about breaks
- Ask what the label says about duration and stopping.
- Ask what monitoring is needed (for example, glucose or IGF-1 for GH peptides).[6]
- Discuss your goal for a break: side effects, cost, travel or a plateau.
- Agree on a restart plan before stopping, including dose.
- Track symptoms and weight during any break and report changes.
Checklist before changing your schedule
- Prescriber agrees to the change
- Restart dose and timing written down
- Monitoring tests scheduled if needed
- Plan for what to watch for while off
Related reading: peptide side effects, how to calculate peptide dosage for restart doses your prescriber sets, and CJC-1295 and ipamorelin.
